RNAssist Blog

Andrew Goldsborough - our CEO, recently visited Rio de Janeiro, Brazil, to meet with the team at Fiocruz / Bio-Manguinhos as part of a joint project focused on TheraPHIX™, RNAss...

The rapid development of RNA vaccines during the COVID-19 pandemic saved millions of lives. However, one major challenge remains: RNA degrades quickly when exposed to heat, enzy...

RNAssist is proud to announce the development of TheraPHIX™, a pioneering solution for mRNA vaccine and therapeutic stability. In collaboration with the Centre for Process Innov...

vivoPHIX has many applications – wherever your research may take you. Here are some photos from a recent project in South East Asia, where we were collecting bacteria from carni...

We are delighted to report that this week RNAssist reagents will be combined with various biological samples aboard the International Space Station in the microgravity condition...

We are delighted to be a partner for the EU-funded NERVSPAN research community that will develop an integrative approach to study various aspects of neuronal physiology througho...

We are delighted that we can make a small contribution to the important work of Dr. Scott Tighe, Technical Director at the Advanced Genomics Lab at the University of Vermont, NA...

RNAssist and Rapid Labs Agree on Manufacturing and Supply Agreement for genoPHIX™ and vivoPHIX™ Biomolecule Stabilisation, Tissue Fixation and Microbial Inactivation Technology....

Studies on cave bacteria have been a valuable research area in both geology and biology, providing insights into the evolution of antibiotic resistance, the role of microbes in...

In a further development of the collaboration between QCMD and RNAssist, QCMD will use the universal biological sample stabilization virusPHIX-P9™ as the matrix within its forth...

Cambridge and Glasgow, UK. 23rd January 2020 – RNAssist. (www.RNAssist.com) a UK company that has developed a universal biological sample stabilization, fixation and inactivatio...